Supernus Pharmaceuticals, Inc. notified Nasdaq of the completion of its merger on November 2, 2026, and requested the suspension and delisting of its common stock. The company intends to deregister its shares and suspend its reporting obligations under the Exchange Act as it will no longer be listed on any national securities exchange.
Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals, Inc.
Supernus Pharmaceuticals completed its previously announced merger with Indivior Pharmaceuticals, with Supernus becoming a wholly owned subsidiary of the combined entity, which has been renamed Supernus, Inc. Supernus stockholders received 1.5401 shares of the combined company for each share held, and the transaction was supported by a new $650 million senior secured term loan facility.
The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.
Term
7 years
“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”
Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals